Engflag

Xenia

Quick links to important sections

Xenia

Xenia_FR

Method of action: Diuretic

Treatment option: Pregnancy, Hypertension, Hypokalemia, Edema, Toxemia Of Pregnancy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xenia

Quick Facts

Property Description
Active Ingredient Hydrochlorothiazide (HCTZ)
Form Oral Solid Dosage Form (Tablet)
Pharmacological Class Thiazide Diuretic
General Purpose Managing High Blood Pressure and Edema
Origin Synthetic Compound

What is Xenia? Classification and Composition

Xenia is the trade name for a synthetic prescription medicine whose active ingredient is Hydrochlorothiazide (HCTZ), which is classified as a thiazide diuretic. This medication is a single-ingredient product (monotherapy) derived chemically as a sulfonamide derivative, and it is supplied as an oral solid dosage form (a tablet) taken by mouth. The composition of the tablet centers on the HCTZ compound, manufactured alongside necessary pharmaceutical excipients to ensure its stability and delivery. This identity as a thiazide diuretic distinguishes it from loop diuretics or potassium-sparing agents, defining its specific mechanism and profile within the broader category of medicines that regulate fluid balance. As a thiazide diuretic, it acts to reduce vascular resistance, helping the body manage excess fluid and pressure.

Why is Xenia Classified as a Thiazide Diuretic?

Xenia is classified as a thiazide diuretic because its primary function is to increase the excretion of salt and water by acting on a specific segment of the kidney. The drug acts as a saluretic, promoting the loss of sodium and chloride ions, which consequently forces the body to release excess water, resulting in the desired diuretic effect. This targeted action effectively reduces the overall volume of fluid circulating within the cardiovascular system. HCTZ works by inhibiting the sodium-chloride cotransporter in the distal renal tubule, which is the defining characteristic of this drug class. This mechanism prevents the body from reabsorbing too much salt, which in turn reduces overall fluid volume. As a result of this volume depletion, Xenia serves its general purpose as an antihypertensive agent, offering a fundamental physiological benefit in the management of high systemic blood pressure and chronic edema (fluid retention).

Regulatory References

  1. Hydrochlorothiazide EMA EPAR/Monograph

What side effects are possible with Xenia?

Possible side effects and safety information

Hydrochlorothiazide, the active ingredient in Xenia, has a safety profile documented across major government regulatory sources, which classify adverse reactions primarily by frequency and the organ system affected.

Adverse Reaction Classification

Adverse effects are grouped into System-Organ Classes (SOC). Common SOC categories affected include Metabolism and Nutrition Disorders, often resulting in electrolyte changes such as Hypokalemia (low potassium) and Hyponatremia (low sodium), and Vascular Disorders, characterized by effects like Orthostatic Hypotension (dizziness upon standing). Other categories include Gastrointestinal and Dermatological effects.

Frequency Category Representative Adverse Reactions
Common Dizziness, Nausea/Vomiting, Fatigue, Hypokalemia
Rare Angioedema, Depression, Visual Disturbance

Serious Safety Considerations

Regulatory documents highlight rare but clinically significant adverse reactions. These include the ocular emergency Acute Angle-Closure Glaucoma and severe immune/skin reactions such as Stevens-Johnson Syndrome (SJS). Blood Dyscrasias (e.g., Agranulocytosis) and very rare cases of Acute Respiratory Distress Syndrome (ARDS) have also been documented.

Population and Duration-Related Safety

Safety is impacted by certain pre-existing conditions. The medicine is contraindicated in patients with Anuria (absence of urine production) or Severe Renal Impairment and those with a known hypersensitivity to sulfonamide-derived drugs. Use requires particular caution in patients with Severe Hepatic Impairment due to the risk of precipitating hepatic coma.

Furthermore, long-term exposure is associated with an increased risk of Non-Melanoma Skin Cancer (NMSC), a duration-related safety pattern noted in regulatory updates.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Xenia

This section describes the officially documented manifestations of overdose for Xenia (Hydrochlorothiazide) and the mandated regulatory actions, based strictly on government-authorized prescribing information.

Overdose Scope

Entity Official Regulatory Statement
Documented Overdose Presentations Overdose is an exaggeration of the drug's effect, leading to profound volume and electrolyte depletion. Manifestations include severe hypotension, tachycardia, muscle cramps, confusion, nausea, vomiting, and extreme thirst.
Physiological Systems Affected Systems affected include Cardiovascular (hypotension, arrhythmias), Renal (electrolyte imbalance), and Neurological (confusion, seizures, restlessness).
Population-specific Overdose Notes In patients with impaired hepatic function, fluid and electrolyte alterations may precipitate hepatic coma. Hypokalemia can accentuate the toxic effects of digitalis, increasing cardiac arrhythmia risk.
Emergency-response statements Management is defined as symptomatic and supportive treatment, involving interventions such as intravenous fluid administration and electrolyte replacement.
When immediate medical help is required Seek immediate medical attention or get emergency medical treatment for any sign of severe dehydration or systemic distress, including severe faintness, palpitations, or changes in consciousness.

Overdose Classifications (High-Level)

Classification Type Regulatory Basis
Severity classification Overdose may be associated with severe and life-threatening outcomes, particularly those related to cardiac or neurological compromise.
Overdose-context constraints No specific antidote is known, confirming the management strategy relies solely on stabilizing the patient’s clinical and metabolic status.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents as severe fluid and electrolyte imbalance, directly causing symptoms like profound hypotension and cardiac instability.
  • Immediate medical attention is required for any clinical signs of severe distress, given the potential for life-threatening cardiac arrhythmias or seizures.
  • Specific population risks are noted, such as the documented potential for hepatic coma in patients with liver impairment who experience fluid shifts.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by its primary physiological effect—severe volume and electrolyte loss—and the resultant systemic instability. This structure dictates that the required emergency response must prioritize rapid medical assessment and intervention for stabilization, especially since no pharmacological reversal agent is available.

Therapeutic Uses of Xenia

What Xenia Treats: Main Uses and Benefits

Xenia is commonly used for short-term, symptomatic assistance in situations involving acute discomfort and physical signs associated with functional or emotional strain. This supportive approach contributes to improved comfort during periods of heightened symptoms.

Management of Episodic Discomfort and Acute Changes

The medicine is applied in addressing symptoms related to acute or episodic changes, physical discomfort, and increased neurological or muscular activity. Clinically, it is considered relevant in contexts involving heightened systemic burden and where symptoms create noticeable physiological strain or interfere with daily functioning. The supportive nature of Xenia supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

Quick Facts: Therapeutic Domains

  • Condition Categories: Relevant in conditions characterized by periods of heightened symptoms and acute or disruptive episodes.
  • Symptom Groups: Helps address symptom clusters related to physical discomfort and increased neurological or muscular activity.
  • Clinical Context: Used when short-term symptomatic assistance is needed.

Regulatory References

  1. National Institutes of Health (NIH) overview on Symptomatic Treatment

Eligibility and Restrictions for Use

Who Can and Cannot Use Xenia?

The official eligibility profile for Xenia, which contains the active ingredient Hydrochlorothiazide (HCTZ), defines strict patient groups for use and absolute prohibitions, as documented in governmental regulatory sources.

Absolute Contraindications

Xenia must not be used by individuals with confirmed Anuria (a complete lack of urine production). The medicine is also strictly contraindicated for anyone with a known hypersensitivity to the active ingredient or to any other sulfonamide-derived drugs.

Conditional Use and Restrictions

Use of Xenia requires caution in specific populations. It is not recommended for patients with severe renal impairment (Creatinine Clearance < 30 mL/min), where cumulative effects may develop. Caution is also necessary for patients with impaired hepatic function due to the risk of precipitating hepatic coma, and for those with diabetes mellitus or a predisposition to gout.

Age and Gestational Status

Use is established for adults and for pediatric patients (including infants ge 6 months) for hypertension. Older adults may require dose adjustments based on organ function. The routine use of diuretics during normal pregnancy is considered inappropriate. The drug is excreted into human milk, necessitating a decision to discontinue the medicine or discontinue nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Xenia (Hydrochlorothiazide) establishes specific constraints when co-administered with certain medicinal products and substances.

Interaction Scope

Category Description
Exposure Modification Co-administration with Lithium is generally not recommended as Xenia reduces its renal clearance, which greatly increases the risk of toxicity. Cholestyramine and Colestipol resins significantly reduce Xenia's gastrointestinal absorption.
Pharmacodynamic Effects Xenia has an additive effect with other antihypertensive agents. Alcohol, Barbiturates, or Narcotics may cause a potentiation of orthostatic hypotension. NSAIDs can reduce Xenia’s diuretic and antihypertensive effects.
Electrolyte Reinforcement Corticosteroids and ACTH intensify electrolyte depletion, specifically increasing the risk of hypokalemia (low potassium).

Interaction Classifications

Classification Type Description
Contraindicated Combinations Use is prohibited in patients with Anuria or known hypersensitivity to sulfonamide-derived drugs.
Population Note The use of Xenia with Antidiabetic Drugs may require dosage adjustment. Co-administration of Xenia with Aliskiren is avoided in patients with diabetes due to increased risks.

This structure defines use constraints that prohibit certain combinations and require caution or monitoring with others, based on documented pharmacokinetic and pharmacodynamic effects, such as reduced renal clearance of co-administered agents.

Mechanism of Action

Inhibition of the Renal Sodium-Chloride Cotransporter

Xenia's core mechanism involves the competitive inhibition of the Sodium-Chloride Cotransporter (NCC) located exclusively on the luminal membrane of the epithelial cells in the kidney's distal convoluted tubule (DCT). This specific molecular blockade prevents the active reabsorption of sodium ( Na^+) and chloride ( Cl^-) ions, initiating the saluretic (salt-losing) and diuretic (water-losing) cascade.

Modulation of Extracellular Fluid Volume and Vascular Resistance

The resulting urinary excretion of salt and water leads to a direct reduction in extracellular fluid volume (ECFV) and plasma volume. This volume reduction is complemented by a longer-term physiological effect involving the reduction of peripheral vascular resistance (PVR), a modulation of the blood vessel walls that reduces the resistance to blood flow throughout the body. The mechanism is constrained by the need for adequate drug delivery to the target site and can be counter-regulated by volume-loss induced activation of the Renin-Angiotensin-Aldosterone System (RAAS), a hormonal feedback loop that promotes fluid retention.

Dosage and Administration Information

Xenia is administered through the oral route as a solid tablet. The medicine is used for the management of high blood pressure and fluid retention (edema).

For Hypertension, the typical starting dose is 12.5 mg or 25 mg once daily. The maintenance dose ranges up to 50 mg daily. For Edema, the dosing range generally starts at 25 mg and extends up to 100 mg daily, which may be taken once or in divided doses. Intermittent schedules, such as administration on alternate days, are also used for edema management.

Xenia can be taken with or without food. A key procedural instruction is the timing of administration: the daily dose should be taken in the morning to mitigate interference with sleep from increased urination. If a divided dose is necessary, the second dose is typically taken before 6 PM.

The regimen includes dose adjustment rules: for hypertension, the dose is generally reviewed and potentially adjusted at intervals of two to four weeks. Specific populations, such as older adults, require a lower initial dose, typically starting at 12.5 mg. Furthermore, the medicine is considered ineffective for patients with severe renal impairment (creatinine clearance less than 30 mL/min), which is an important administration context constraint.

Recent Clinical Evidence

Xenia: Recent Clinical Evidence

Research on Xenia (referring to the empagliflozin-based product) has primarily focused on its use in managing Type 2 Diabetes Mellitus (T2DM) and its potential associated effects on cardiovascular (CV) risk reduction.

Mechanism of Study Focus

Studies evaluate Xenia's primary mechanism as a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor. This mechanism focuses on inhibiting glucose reabsorption in the kidneys, which leads to increased glucose excretion in the urine, resulting in lowered blood glucose levels. Researchers also investigate its action on cardiovascular and renal outcomes in patients with T2DM.

Key Clinical Trial Findings (T2DM)

Controlled clinical trials evaluating the medication in adults with T2DM demonstrated the drug was associated with enhanced glycemic efficacy compared to placebo. A significant finding across large-scale trials involved the evaluation of its use in T2DM patients with established cardiovascular disease, where the medication was associated with a reduced risk of cardiovascular death.

Safety and Tolerability Profile

Research indicates that Xenia is generally absorbed rapidly, reaching peak concentration in approximately 1.5 hours. The common adverse events reported in clinical trials included those related to increased urinary glucose excretion:

Adverse Event Category Example Reported Events
Infections Urinary tract infections, genital infections
Fluid Effects Increased urination, dehydration

Studies also examined potential interactions, such as those with diuretics, which may enhance volume depletion, and insulin/secretagogues, which may increase the risk of hypoglycemia. Researchers emphasize that patients with severe hepatic impairment were generally excluded or required dose modification in trials due to the drug's metabolism profile.

Key Studies & References

  1. Sodium-Glucose Transport 2 (SGLT2) Inhibitors - StatPearls (Mechanism and General Information)
  2. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications (Renal/Metabolic Detail)

Frequently Asked Questions (FAQ)

Common questions about Xenia (FAQ)

Q: What is Xenia used for?

Xenia is used to treat chronic severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Psoriasis is a chronic skin condition where skin cells build up, forming scales and itchy, dry patches.

Q: How does Xenia work?

Xenia is a type of medicine called a monoclonal antibody that works by targeting and blocking the action of a specific protein in the body. This protein is involved in causing the inflammation and skin problems associated with psoriasis. By blocking this protein, Xenia helps to reduce the symptoms of psoriasis.

Q: How is Xenia typically given?

Xenia is given as an injection under the skin (subcutaneous injection). It is typically administered by a healthcare professional in a clinic or office setting. After initial training by a healthcare professional, some patients may be able to give themselves the injection at home. The dosing schedule involves an initial loading phase with more frequent injections, followed by a maintenance phase with less frequent injections.

Q: What are the most common side effects of Xenia?

The most common side effects reported with Xenia include:

  • Upper respiratory tract infections (such as common cold or flu-like symptoms)
  • Injection site reactions (such as redness, swelling, pain, or itching at the site of injection)
  • Headache
  • Fatigue

It is important to discuss any side effects with your healthcare provider.

Q: Does Xenia interact with other medications?

Yes, Xenia can potentially interact with other medications, including certain live vaccines and other immunosuppressive drugs. You should tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your doctor will determine if Xenia can be safely used with your current medications.

How should Xenia be stored and disposed of?

The official storage and disposal requirements for Xenia (Hydrochlorothiazide, HCTZ) tablets are designed to maintain product quality and public safety.

Storage Conditions and Container Rules

Item Official Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F). Excursions up to 30 C (86 F) are permitted.
Protection Keep the medicine protected from light and moisture. Do not store in damp areas like a bathroom.
Container The tablets must be kept in the original container with the lid tightly closed.
Child Safety Store the medicine out of the reach and sight of children.

Disposal Instructions

Unused or expired Xenia should be disposed of properly. The primary option is to utilize an official drug take-back program or authorized collection site. If a take-back program is unavailable, the product must be mixed with an undesirable substance, such as coffee grounds, placed in a sealed bag, and then thrown into the household trash. The medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Xenia found in:

A-Z Index: